AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 0.467 |
| Open | 0.499 |
| Bid | 0.000 x 800 |
| Ask | 0.000 x 800 |
| Day's Range | 0.465 - 0.499 |
| 52 Week Range | 0.350 - 4.950 |
| Volume | 1,421,925 |
| Avg. Volume | 1,894,550 |
| Market Cap | 40.83M |
| Beta | 1.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.390 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- Business Wire•2 days ago
AMPIO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ampio Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. .
- PR Newswire•9 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ampio Pharmaceuticals, Inc. (AMPE)
NEW YORK , Aug. 10, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ampio Pharmaceuticals, Inc. ("Ampio" ...
- Business Wire•9 days ago
INVESTIGATION REMINDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The purpose of the Form 8-K was to provide an update on the FDA’s review of Ampion, and specifically the AP-003-A and AP-003-C trials. Ampio informed the market that it met with the FDA in July, 2018, and received a response letter after that meeting which stated, “as a single trial[,] the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support [the Biologics License Application].” The FDA also stated, “the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.” Based on this news, shares of Ampio fell almost 79% on August 8, 2018.
- ACCESSWIRE•10 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 9, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. ("Ampio" or "the Company") (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The purpose of the Form 8-K was to provide an update on the FDA's review of Ampion, and specifically the AP-003-A and AP-003-C trials. Ampio informed the market that it met with the FDA in July, 2018, and received a response letter after that meeting which stated, "as a single trial[,] the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support [the Biologics License Application]." The FDA also stated, "the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial." Based on this news, shares of Ampio fell almost 79% on August 8, 2018.
- PR Newswire•10 days ago
AMPIO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ampio Pharmaceuticals, Inc. To Contact The Firm
NEW YORK , Aug. 9, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") ...
- PR Newswire•10 days ago
Ampio Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
ENGLEWOOD, Colo., Aug. 9, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio"), a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock and warrants to purchase up to 20,000,000 shares of common stock, at a combined purchase price of $0.40 per share of common stock and accompanying warrant, with anticipated gross proceeds of $8.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ampio. The warrants are exercisable six months after issuance at a price of $0.40 per share of common stock and have a term of five years commencing six months after issuance.
- ACCESSWIRE•10 days ago
Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and Ampio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / While it wasn’t the numbers Inovio reported in its second quarter financial report, it was a positive update on its phase 3 Reveal 1 clinical study of VGX-3100 ...
- Business Wire•11 days ago
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) (NYSE: AMPE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The purpose of the Form 8-K was to provide an update on the FDA’s review of Ampion, and specifically the AP-003-A and AP-003-C trials. Ampio informed the market that it met with the FDA in July, 2018, and received a response letter after that meeting which stated, “as a single trial[,] the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support [the Biologics License Application].” The FDA also stated, “the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial.” Based on this news, shares of Ampio fell almost 79% on August 8, 2018.
- PR Newswire•11 days ago
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
ENGLEWOOD, Colo., Aug. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio"), a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Ampio, with the net proceeds to be used for working capital and general corporate purposes, including continued preclinical development of Ampion and funding an Ampion clinical trial, if required. The sale of the common stock and the accompanying warrants to purchase shares of common stock is being offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017.
- GlobeNewswire•11 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ampio Pharmaceuticals, Inc.
NEW YORK, Aug. 08, 2018-- Levi & Korsinsky announces it has commenced an investigation of Ampio Pharmaceuticals, Inc. concerning possible violations of federal securities laws.. On August 7, 2018, Ampio ...
- PR Newswire•11 days ago
Investor Alert: Kaplan Fox Announces Investigation Of Ampio Pharmaceuticals, Inc.
NEW YORK , Aug. 8, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) is investigating Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) concerning ...
- Business Wire•11 days ago
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Ampio Pharmaceuticals, Inc. – AMPE
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ampio Pharmaceuticals, Inc. resulting from allegations that Ampio may have issued materially misleading business information to the investing public.
- Motley Fool•11 days ago
Here's Why Ampio Pharmaceuticals Inc. Became a Penny Stock Today
The company's lead drug candidate just received some bad news from the FDA.
- PR Newswire•11 days ago
AMPE Alert: Bernstein Liebhard LLP Announces Investigation Of Ampio Pharmaceuticals, Inc. - AMPE
NEW YORK, Aug. 8, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE MKT: AMPE) resulting from allegations that Ampio and/or its executives may have issued materially misleading business information to the investing public. If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit Ampio Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com. On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with the SEC providing a regulatory update of the FDA's review of Ampion, including the AP-003-A trial.
- MarketWatch•11 days ago
Ampio's stock plunges below $1 threshold after FDA comments on clinical trial
Shares of Ampio Pharmaceuticals Inc. (ampe) plunged 69% in morning trade Wednesady, to fall back below the $1 threshold for the first time in 10 months, after the biopharmaceutical company said the Food and Drug Administration said a current trial for a treatment of osteoarthritis of the knee did not support a biologics license application (BLA). The FDA said the that as a single trial, the AP-003-A trial on its own does not appear to provide sufficient evidence of effectiveness to support a BLA. The FDA recommended an additional randomized trial.
- ACCESSWIRE•11 days ago
Today's Research Reports on Trending Tickers: Ampio Pharmaceuticals and OPKO Health
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / U.S. equities closed up on Tuesday, as investors set aside trade related concerns and focus on strong corporate earnings. The Dow Jones Industrial Average increased ...
- PR Newswire•13 days ago
Ampio Hosting Conference Call Tuesday, August 7, 4:30 pm EDT to Update the Preparation of the Biologics License Application (BLA) for Ampion™
ENGLEWOOD, Colo. , Aug. 6, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference call Tuesday, August 7th at 4:30 pm EDT to update the preparation of the Biologics License ...
- PR Newswire•17 days ago
Ampio Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
ENGLEWOOD, Colo. , August 2, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...
- ACCESSWIRE•27 days ago
Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Ampio Pharmaceuticals and Sorrento Therapeutics both saw big moves in opposite directions on Friday. Ampio Pharmaceuticals, Inc. shares closed up 11.44% on Friday with trading volume roughly three times higher than usual at 2,251,564 shares traded. It was recently revealed that Susquehanna International Group Llp has increased its position in the stock by $57,249.
- PR Newswire•last month
Ampio provides a Link to New Publication on the Mechanism of Action for Ampion™
ENGLEWOOD, Colo., July 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" authored by Dr. Bar-Or and prominent clinicians has been published online in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained: "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A). Here, we show that Ampion significantly decreases the release of pro-inflammatory biomarkers from LPS-stimulated macrophages and that one of the known components of Ampion (N-acetyl kynurenine or NAK) also decreased these biomarkers When an inhibitor of the aryl hydrocarbon receptor (AhR) was included, the anti-inflammatory effect of Ampion was partially blocked while the effect of NAK was completely prevented.
- ACCESSWIRE•2 months ago
Free Pre-Market Technical Recap on Sarepta Therapeutics and Three Additional Biotech Stocks
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
- PR Newswire•2 months ago
Ampio Reports New Publication on the Mechanisms of Action for Ampion™
ENGLEWOOD, Colo., June 27, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a basic science manuscript entitled "The Anti-Inflammatory Effect of LMWF5A and N-Acetyl Kynurenine on Macrophages: Involvement of Aryl Hydrocarbon Receptor in Mechanism of Action" has been accepted for publication in Biochemistry and Biophysics Reports. Dr. David Bar-Or, Ampio's CSO explained, "This biochemical research uncovered an important part of the mechanism of action of Ampion™ or the low molecular weight fraction of 5% human serum albumin (LMWF5A).
- ACCESSWIRE•2 months ago
Today's Research Reports on Stocks to Watch: bluebird and Ampio Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / June 25, 2018 / bluebird shares were in the red on Friday, retreating after several days of gains after an Evercore ISI analyst upgrade the stock to "outperform" and ...
- PR Newswire•2 months ago
Ampio Provides Scientific Update and Links to Peer Review Publications
ENGLEWOOD, Colo., June 5, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced two peer-reviewed articles on the clinical application of Ampion™ are now available online. "Peer-reviewed journals are an important part of the scientific process, which requires intensive scrutiny by other experts in the field of any manuscript submitted before publication. Ampion™ is the 'Low Molecular Weight Fraction of 5% human serum Albumin' (LMWF-5A) that is in development to treat severe osteoarthritis of the knee (OAK).
- PR Newswire•3 months ago
Ampio Updates Regulatory and IP Activities
The Company and the FDA have agreed to a July 2018 meeting to continue their discussions on the BLA submission being prepared for Ampion™ as a treatment of the signs and symptoms of severe (KL4) osteoarthritis-of-the- knee (OAK). Ampio was awarded US patent (9,956,217 B2) titled: "Treatment of Joint conditions" that provides method protection, until the year 2035, for multiple injections of Ampion™. This is supported by the fully enrolled Open-Label Extension (OLE) study for the assessment of the clinical safety for long-term treatment with Ampion (up to 5 yearly injections) that will conclude in 2019 and the completed (published) 3 injections trial (STRUT or AP-007).
